Figure 22. NMB (£20,000 per QALY threshold) varying the RR for azithromycin.

Figure 22NMB (£20,000 per QALY threshold) varying the RR for azithromycin

NMB, net monetary benefit at a £20,000 threshold: no treatment, −£54,700; prednisolone, −£39,018; ibuprofen, −£45,767; fluticasone, −£188,751; azithromycin, dependent on the RR

From: Appendix K, Health Economics

Cover of Cystic Fibrosis
Cystic Fibrosis: Diagnosis and management.
NICE Guideline, No. 78.
National Guideline Alliance (UK).
Copyright © NICE 2017.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.